Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Genetic and structural basis of the human anti-alpha-galactosyl antibody response

PROVIDER: PRJNA851943 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19789900.fastq.gz	Fastqsanger.gz
	SRR19789901.fastq.gz	Fastqsanger.gz
	SRR19789902.fastq.gz	Fastqsanger.gz
	SRR19789903.fastq.gz	Fastqsanger.gz
	SRR19789904.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

E-GEOD-11959

Project description:Transcription profiling by array of human SK-N-AS neuroblastoma xenograft tumor treated with anti-human IGF-IR monoclonal antibody (h10H5) to study the anti-tumour function of the antibody

2025-01-16 | E-GEOD-11959 | ExpressionAtlas

E-GEOD-47087

Project description:Gene expression alterations in human colon cancer xenograft treated with anti-VEGF antibody

2025-01-24 | E-GEOD-47087 | ExpressionAtlas

Effect anti-TNF-alpha treatment on CD4+ T cell activation

Project description:The experiment was designed to test how autocrine TNF-alpha impacts human CD4+ T cell activation. Naïve CD4+ T cells from healthy human blood donors were either left unactivated or activated with anti-CD3/anti-CD28 in presence of an isotype control antibody or anti-TNF-alpha antibody. RNA was extracter at 48 hours. Analysis revealed that anti-TNF-alpha treatment prevented upregulation of activation-induced T cell metabolic, signaling and effector molecules.

2024-07-25 | GSE238247 | GEO

Genetic Study of anti-EGFR Antibody Therapy Response in Colorectal Carcinoma

Project description:Genetic Study of anti-EGFR Antibody Therapy Response in Colorectal Carcinoma

| PRJNA498496 | ENA

Proteomic analysis of pemphigus autoantibodies indicates a much larger, more diverse, and dynamic repertoire than determined by B-cell genetics

Project description:Genetic techniques such as antibody phage display have indicated an oligoclonal autoantibody response in various autoimmune diseases including pemphigus. These techniques have limited sampling of B cell clones. Characterization by mass spectometry of pemphigus serum autoantibodies affinity-purified on the autoantigen desmoglein indicates a much more polyclonal response. Conversely, many genetically detectable anti-desmoglein B cells do not contribute detectably to the serum antibody response. There is no convergence of the autoantibody response among patients, as determined by CDR3 sequence or heavy chain variable gene usage, implying targeting of these genes will not be a useful therapeutic strategy. Longitudinal analysis of autoantibodies over years indicates that, although many antibody clones persist, the proportion of each clonal antibody changes. These studies indicate a dynamic and very diverse autoantibody response not revealed by genetic studies, and explain why similar overall anti-desmoglein titers may give variable disease activity.

2016-11-30 | MSV000080368 | MassIVE

Macaca fascicularis isolate:CYM10710 | breed:Chinese-origin

Project description:Vaccine elicitation and structural basis for broad antibody protection against alphaviruses

| PRJNA951758 | ENA

E-MTAB-2533

Project description:Transcriptional and epigenetic basis for restoration of G6PD enzymatic activity in human G6PD-deficient cells

2025-01-23 | E-MTAB-2533 | ExpressionAtlas

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis

Project description:Infliximab, an anti-TNF-alpha monoclonal antibody, is an effective treatment for ulcerative colitis (UC) with over 60% of patients responding to treatment and up to 30% reaching remission. The mechanism of resistance to anti-TNF-alpha is unknown. This study used colonic mucosal gene expression to provide a predictive response signature for infliximab treatment in UC. Keywords: drug response

2010-01-07 | GSE14580 | GEO

E-MTAB-2960

Project description:CD3/CD28 and IL-2 stimulated mouse CD8 T cells with or without anti-CD132 blocking antibody

2014-09-24 | E-MTAB-2960 | ExpressionAtlas

Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101

Project description:The purpose of this study is evaluate the pharmacokinetics, pharmacodynamics, immunogenicity and anti-tumor effect of of fully human anti - VEGF monoclonal antibody LY00101 and explore the potential prognostic and predictive biomarkers. This study will not take into account the results of molecular-genetic tests of patients enrolled in the study

| 2282087 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data